This episode is an interview with Dr. Wouter Vaes, the Chief Science Officer of Peregrion. We discuss how accelerator mass spectrometry is being used in early clinical development for drug metabolism and pharmacokinetics. We discuss using this technology to support development of oncology agents, determining absolute bioavailability without IV toxicology work, and more.
Links discussed in the show:
You can contact Wouter by email: wouter.vaes@peregrion.com
Podden och tillhörande omslagsbild på den här sidan tillhör
Nathan Teuscher. Innehållet i podden är skapat av Nathan Teuscher och inte av,
eller tillsammans med, Poddtoppen.
